Pure Lithium and CEO Emilie Bodoin Recognized for Innovations at Reuters Global Energy Transition Awards
26.6.2025 19:27:00 EEST | Business Wire | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that it has won the 2025 Reuters Global Energy Transition award for R&D Achievement.
The award, presented at a June 24th ceremony in New York, recognizes research and development projects that promote a science-oriented energy transition while yielding promising potential and achievement.
Pure Lithium has developed lithium metal batteries with double the energy density of lithium-ion cells and an industry-leading cycle life. By prioritizing research and development, the company achieved step-change advancements in battery technology and has built a strong portfolio of 119 patents and applications.
“We’re thrilled to be selected for this prestigious award, which recognizes the hard work, dedication and creativity of our world-class team,” said Pure Lithium Founder and CEO Emilie Bodoin. “We know that commercializing a new chemistry requires a delicate balance of R&D, while maintaining laser focus on practical use cases. At Pure Lithium we have been able to strike that balance and innovate tremendously while in parallel creating a robust technology that is economically viable.”
Bodoin personally received a “highly recommended” recognition as an Innovator in Energy Award. The award celebrates individuals who have made significant contributions to advancing energy production or solutions – including groundbreaking innovation, pioneering new technologies, practices, as well as creating strategies that enhance energy efficiency, sustainability, and accessibility.
Pure Lithium’s Brine to Battery™ technology seamlessly integrates lithium extraction with lithium metal anode production. The technology enables the production of lithium metal batteries in a charged state, simplifying the existing lithium-ion battery manufacturing process by eliminating the need for many steps in the formation and aging process, which account for 35% of gigafactory capex and 41% of associated manufacturing costs. Additionally, Pure Lithium eliminates the use of graphite, nickel, cobalt and manganese with a high-capacity vanadium cathode, effectively dependence on China.
Pure Lithium would like to extend our gratitude to the judges and to Reuters Events for putting on an excellent celebration of energy transition technologies and leadership across industries. As we move toward commercialization of our lithium metal battery, being chosen out of a dynamic group of nominees is a further validation of our efforts to radically transform battery technology.
About Pure Lithium
Pure Lithium is a disruptive Boston-based lithium metal battery technology company led by inventor and lithium expert, CEO Emilie Bodoin, and world-renowned battery and metallurgical expert, MIT Emeritus Professor Donald R. Sadoway, as full-time CSO. The Company's novel Brine to Battery™ technology combines metal extraction and anode production, unlocking unconventional sources of lithium. The resulting pure lithium metal anode is the core component of our lithium metal vanadium oxide battery, a step-change improvement over today’s lithium-ion technology in cell performance, cost, and safety. Additionally, the battery is free of graphite, cobalt, nickel, and manganese. For more information, visit www.purelithium.io or email news@purelithium.io.
About Reuters Global Energy Transition Events
Amidst increased pressure from climate risk and the energy crisis, global energy and industrial business leaders are tasked with transforming their businesses and driving progress towards zero-carbon energy. Recognition and celebration are critical for benchmarking, reaching consensus and uniting the industry on a shared energy transition pathway.
As The Trusted Voice of the Energy Transition, Reuters Events has a legacy of convening the most senior and diverse global leaders from throughout the energy, industrial, finance and government sectors to drive inter-sectoral collaboration and action.
To further amplify those leading and catalyzing progress, we are proud to launch the Reuters Events: Global Energy Transition Awards 2025 at our flagship summit in New York, providing an unbiased, inclusive and influential platform for you to demonstrate excellence, achievement and innovation to the full transition ecosystem. The energy transition is both a social and business imperative. We look forward to spotlighting excellence, recognizing those leading the way, and connecting global leaders committed to a sustainable future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250626250563/en/
Contacts
Ross Larsen
Head of Editorial, 33 Communications
Purelithium@thirtythreecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom